胰岛素
国家(计算机科学)
业务
医学
内分泌学
计算机科学
算法
作者
Kelly E. Anderson,Nathorn Chaiyakunapruk,Eric J. Gutierrez,Howard Weston Schmutz,Michael R. Rose,Diana Brixner,R. Brett McQueen
出处
期刊:Health Affairs
[Project Hope]
日期:2024-08-01
卷期号:43 (8): 1137-1146
标识
DOI:10.1377/hlthaff.2024.00118
摘要
Nearly all patients with type 1 diabetes and 20-30 percent of patients with type 2 diabetes use insulin to manage glycemic control. Approximately one-quarter of patients who use insulin report underuse because of cost. In response, more than twenty states have implemented monthly caps on insulin out-of-pocket spending, ranging from $25 to $100. Using a difference-in-differences approach, this study evaluated whether state-level caps on insulin out-of-pocket spending change insulin usage among commercially insured enrollees. The study included 33,134 people ages 18-64 who had type 1 diabetes or who used insulin to manage type 2 diabetes with commercial insurance coverage that was subject to state-level oversight and was included in the 25 percent sample of the IQVIA PharMetrics database during 2018-21. Insulin out-of-pocket caps did not significantly increase quarterly insulin claims for enrollees who had type 1 diabetes or who used insulin to manage type 2 diabetes. State-level caps on insulin out-of-pocket spending for commercial enrollees did not significantly increase insulin use; that may be in part because of out-of-pocket expenses being lower than cap amounts.
科研通智能强力驱动
Strongly Powered by AbleSci AI